Treatment of Primary Axillary Hyperhidrosis with Two Doses of Botulinum Toxin A-Observational Study.
María Jesús AntónErnesto Domingo Candau PérezMaría Pilar Bermejo de la FuentePublished in: Toxins (2024)
Hyperhidrosis (HH) is defined as the production of more sweat than is necessary for its thermoregulatory function, negatively affecting patients' quality of life and interfering with their social, work and family life. In this context, the aim of thisstudy was to evaluate the efficacy of two different doses of botulinum toxin type A (50 or 100 units) in each axilla in severe primary axillary hyperhidrosis. A descriptive, observational, cross-sectional and post-authorisation study was conducted onpatients referred to our department.Thirty-one patients with severe primary axillary hyperhidrosis were included, some of whom received more than one infiltration during the follow-up period, performing a total of 82 procedures. They were assigned by simple random sampling to two types of treatment: infiltration of 50 or 100 units (U) of botulinum toxin A per axilla.Hyperhidrosis severity was assessed using the Hyperhidrosis Disease Severity Scale (HDSS), and quality of life was assessed using the Dermatology Life Quality Index (DLQI) questionnaire. Onabotulinum toxin A infiltration reduced the severity of hyperhidrosis and improved the quality of life of the treated patients, with no significant differences between the two groups.
Keyphrases
- botulinum toxin
- cross sectional
- sentinel lymph node
- lymph node
- neoadjuvant chemotherapy
- end stage renal disease
- newly diagnosed
- ejection fraction
- escherichia coli
- healthcare
- chronic kidney disease
- early onset
- mental health
- early stage
- peritoneal dialysis
- radiation therapy
- combination therapy
- prognostic factors
- locally advanced